• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Revelyst Announces Chief Supply Chain Officer

    4/23/24 7:00:00 AM ET
    $BDX
    $EMBC
    $VSTO
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer.

    Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply chain, sourcing and logistics leader is key to helping Revelyst and its brands begin this new chapter.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423438660/en/

    Joe Beck, Chief Supply Chain Officer for Revelyst (Photo: Business Wire)

    Joe Beck, Chief Supply Chain Officer for Revelyst (Photo: Business Wire)

    Beck most recently served as Vice President of Global Supply Chain for embecta (NASDAQ:EMBC), a medical technology company where he oversaw global supply chain and distribution operations, including the overhaul of their global network design, planning, logistics, and trade technology and change management leadership. Beck was part of embecta's leadership team executing the separation from Becton Dickinson and Co. (NYSE:BDX). During the transition, he helped establish the company's supply chain infrastructure while ensuring continuity of supply and mitigating customer disruptions. His ability to design and deploy global supply chain operations for a standalone business — including hiring talent, building effective teams and developing processes, analytics and technology — made him an ideal candidate to be Revelyst's first Chief Supply Chain Officer.

    "Bringing a change agent like Joe to Revelyst's leadership team is critical for our goal of becoming the industry's No. 1 house of brands," said Eric Nyman, CEO of Revelyst. "He has a unique talent for transforming a company's supply chain by consolidating facilities and building new capabilities, which have a direct impact on the bottom line. Joe will help revolutionize Revelyst at the enterprise, platform and brand level, and we welcome his innovative thinking as we continue to build our culture of empowerment and excellence."

    Before embecta, Beck worked for Medtronic and UPS, two global Fortune 500 companies where he streamlined and optimized supply chain operations, which he will replicate and enhance in this new role. Beck is the latest executive to join Revelyst's growing management team, including Nyman, CFO Andy Keegan, General Counsel Jung Choi and CHRO Joyce Butler. The addition of Beck will provide Revelyst with the supply chain and sourcing savvy needed in an increasingly competitive and complex global economy.

    "This is the opportunity of a lifetime because it combines my outdoor passions with my love of helping companies become more efficient and effective moving products and information across the global supply chain," said Beck. "I look forward to building a world-class team whose sole focus is optimizing the way Revelyst does business, building scale across our portfolio and developing innovative strategies that give our company and our brands a significant competitive advantage to accelerate growth."

    About Revelyst

    Revelyst, a segment of Vista Outdoor Inc. (NYSE:VSTO), is a collective of world-class maker brands that design and manufacture performance gear and precision technologies. Our category-defining brands leverage meticulous craftsmanship and cross-collaboration to pursue new innovations that redefine what is humanly possible in the outdoors. Portfolio brands include Foresight Sports, Bushnell Golf, Fox, Bell, Giro, CamelBak, Bushnell, Simms Fishing and more. For more information, visit our website at www.revelyst.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240423438660/en/

    Get the next $BDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX
    $EMBC
    $VSTO

    CompanyDatePrice TargetRatingAnalyst
    Becton Dickinson and Company
    $BDX
    5/22/2025$185.00Buy → Neutral
    Citigroup
    Becton Dickinson and Company
    $BDX
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    Becton Dickinson and Company
    $BDX
    5/2/2025$192.00Buy → Neutral
    Goldman
    Becton Dickinson and Company
    $BDX
    5/2/2025Outperform → Mkt Perform
    Raymond James
    Becton Dickinson and Company
    $BDX
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    Becton Dickinson and Company
    $BDX
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    Becton Dickinson and Company
    $BDX
    5/1/2025Outperform → Mkt Perform
    William Blair
    Embecta Corp.
    $EMBC
    4/10/2025$15.00Neutral
    Mizuho
    More analyst ratings

    $BDX
    $EMBC
    $VSTO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Human Resources Officer Casner Jean covered exercise/tax liability with 916 shares, decreasing direct ownership by 2% to 48,799 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    8/11/25 5:06:47 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Fraser Claire sold $165,955 worth of shares (863 units at $192.30), decreasing direct ownership by 4% to 23,143 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/8/25 6:56:58 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BD to Present at Wells Fargo 2025 Healthcare Conference

    FRANKLIN LAKES, N.J., Aug. 14, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025 at 8:00 a.m. Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the

    8/14/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results

    PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025. "Q3 was a strong quarter for embecta, reflecting solid commercial execution, aided in part by the timing of customer orders. Despite an increasingly complex and dynamic geopolitical environment, given the year-to-date performance and our outlook for the remainder of the year, we are tightening and raising our fiscal 2025 outlook for key financial metrics," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdi

    8/8/25 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow

    8/8/25 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Becton Dickinson downgraded by Citigroup with a new price target

    Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00

    5/22/25 8:18:13 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00

    5/2/25 8:06:47 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson downgraded by Goldman with a new price target

    Goldman downgraded Becton Dickinson from Buy to Neutral and set a new price target of $192.00

    5/2/25 8:06:36 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BDX
    $EMBC
    $VSTO
    SEC Filings

    View All

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    5/23/25 4:35:56 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/25/25 4:26:16 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

    SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)

    8/14/25 9:01:17 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Embecta Corp.

    10-Q - Embecta Corp. (0001872789) (Filer)

    8/8/25 11:44:34 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Embecta Corp. (0001872789) (Filer)

    8/8/25 7:01:25 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Leadership Updates

    Live Leadership Updates

    View All

    BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

    FRANKLIN LAKES, N.J., July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy. Mushin will serve as a member of the BD Executive Leadership Team reporting to Tom Polen, chairman, CEO and president of BD and will lead the strategy development to support an effective transition into this new structure over the next several months.

    7/7/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Names Gregory J. Hayes to Board of Directors

    FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development f

    3/27/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $BDX
    $EMBC
    $VSTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Vista Outdoor Inc.

    SC 13G - Vista Outdoor Inc. (0001616318) (Subject)

    12/2/24 4:30:15 PM ET
    $VSTO
    Ordnance And Accessories
    Industrials

    SEC Form SC 13G filed by Vista Outdoor Inc.

    SC 13G - Vista Outdoor Inc. (0001616318) (Subject)

    11/27/24 12:42:04 PM ET
    $VSTO
    Ordnance And Accessories
    Industrials

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/8/24 10:57:43 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Financials

    Live finance-specific insights

    View All

    Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results

    PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025. "Q3 was a strong quarter for embecta, reflecting solid commercial execution, aided in part by the timing of customer orders. Despite an increasingly complex and dynamic geopolitical environment, given the year-to-date performance and our outlook for the remainder of the year, we are tightening and raising our fiscal 2025 outlook for key financial metrics," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdi

    8/8/25 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow

    8/8/25 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    BD Reports Third Quarter Fiscal 2025 Financial Results

    Revenue of $5.5 billion increased 10.4% as reported, 8.5% adjusted FXN and 3.0% organicGAAP and adjusted diluted EPS grew to $2.00 and $3.68, respectivelyGAAP and adjusted gross margin up 160 basis points and 50 basis points, respectively, driven by BD ExcellenceGAAP and adjusted operating income up 46.6% and 11.3%, respectivelyCompany raises full-year adjusted diluted EPS guidance to $14.30 to $14.45, reflecting an $0.18 increase to 9.4% growth at the midpoint, while reaffirming organic revenue growth guidance1Expects to complete remaining $250 million of $1 billion share buyback commitment by the end of fiscal 2025FRANKLIN LAKES, N.J., Aug. 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and

    8/7/25 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care